Recommended Topic Related To:


"Colorectal cancer is the second leading cancer killer among men and women in the United States, after lung cancer. About 1 in 3 adults is not getting screened for colorectal cancer as recommended by the U.S. Preventive services Task Force (USP"...


(regorafenib) Tablets



  • Severe and sometimes fatal hepatotoxicity has been observed in clinical trials [see WARNINGS AND PRECAUTIONS].
  • Monitor hepatic function prior to and during treatment [see WARNINGS AND PRECAUTIONS].
  • Interrupt and then reduce or discontinue Stivarga for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence [see DOSAGE AND ADMINISTRATION].


Stivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:

STIVARGA (regorafenib) Structural Formula Illustration

Regorafenib is a monohydrate and it has a molecular formula C21H15ClF4N4O3 • H2O and a molecular weight of 500.83. Regorafenib is practically insoluble in water, slightly soluble in acetonitrile, methanol, ethanol, and ethyl acetate and sparingly soluble in acetone.

Stivarga tablets for oral administration are formulated as light pink oval shaped tablets debossed with “BAYER” on one side and “40” on the other. Each tablet contains 40 mg of regorafenib in the anhydrous state, which corresponds to 41.49 mg of regorafenib monohydrate, and the following inactive ingredients: cellulose microcrystalline, croscarmellose sodium, magnesium stearate, povidone, and colloidal silicon dioxide. The film-coating contains the following inactive ingredients: ferric oxide red, ferric oxide yellow, lecithin (soy), polyethylene glycol 3350, polyvinyl alcohol, talc, and titanium dioxide.

Last reviewed on RxList: 3/7/2013
This monograph has been modified to include the generic and brand name in many instances.


Additional Stivarga Information

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.